DUBLIN–(BUSINESS WIRE)–The “Biosimilars
Market Size, Share & Trends Analysis Report By Product, By Application
(Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune
Disorders), By Region, And Segment Forecasts, 2018 – 2025”
report has been added to ResearchAndMarkets.com’s
The global biosimilars market size is expected to reach a value of USD
61.47 billion by 2025 and is expected to expand at a CAGR of 34.2% over
the forecast period.
Major biological drugs are approaching the patent cliff. This is the
most significant driving factor for the market. For instance, Roche’s
MabThera/Rituxan (rituximab), a monoclonal antibody biologics was
approved by the U.S. Food and Drug Administration (FDA) in November 1997
and its U.S. patent expired in September 2016. Several companies such as
Amgen, Boehringer Ingelheim, and Pfizer are focusing on development of
biosimilar drug of rituximab.
Furthermore, lower cost of biosimilars compared to patented biologics
and positive outcomes in clinical trials are expected to boost market
growth. For instance, in July 2016, Allergan plc and Amgen stated
results from a Phase 3 clinical study of ABP 980 compared with
trastuzumab, a recombinant DNA-derived humanized monoclonal antibody.
This drug was approved for early and metastatic breast cancer and
metastatic gastric cancer in many regions.
Currently, there is a boom in pharmaceutical industry for the
development of biosimilar drugs, which is a cost-saving alternative to
biologic drugs. Amgen Inc., Sandoz International GmbH, Teva
Pharmaceutical Industries Ltd., Pfizer Inc., Biocon, Samsung Bioepis,
and Mylan N.V are some of the companies focusing on the development and
production of biosimilars.
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Biosimilars Market Variables, Trends & Scope
Chapter 4 Biosimilars Market: Product Estimates & Trend Analysis
Chapter 5 Biosimilars Market: Application Estimates & Trend Analysis
Chapter 6 Biosimilars Market: Regional Estimates & Trend Analysis, by
Product and Application
Chapter 7 Competitive Landscape
- Amgen Inc.
- F Hoffmann-La Roche Ltd
- Sandoz International GmbH
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Samsung Bioepis
- Mylan N.V.
- Celltrion Healthcare
- AbbVie Inc.
For more information about this report visit https://www.researchandmarkets.com/research/32rs43/biosimilars?w=4
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900